Features of immune checkpoint inhibitor therapies in patients with hepatocellular carcinoma / 中华肝胆外科杂志
Chinese Journal of Hepatobiliary Surgery
;
(12): 75-80, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-868767
ABSTRACT
The disease burden of hepatocellular carcinoma (HCC) remains large both in China and globally.In particular,advanced HCC lacks of effective systemic therapeutic drugs.Recently immune checkpoint inhibitors such as nivolumab and pembrolizumab have been approved for second-line treatment in patients with advanced HCC by the U.S.Food and Drug Administration (FDA).Compare with traditional chemotherapy or targeted therapy,these novel pharmacological approaches have unique therapeutic features,such as durable response,delayed response and manageable safety profile with specific immune-related adverse events that require monitoring.We aim to summarize the characteristics of immuno-oncology therapies on aspects of long-term outcome,response mechanisms and assessment,safety,and special populations,based on clinical trials and real-world data on patients with HCC.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Hepatobiliary Surgery
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS